within Pharmacolibrary.Drugs.ATC.G;

model G04BE08
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 3.9999999999999996e-05,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.063,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005833333333333333,
    Tlag           = 2160,            
    Vdp             = 0.208,
    k12             = 32,
    k21             = 32
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G04BE08</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor used for the treatment of erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension. It is an orally administered drug, approved and widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult males after a single oral dose administration.</p><h4>References</h4><ol><li><p>Shen, X, et al., &amp; Luo, W (2020). The Effect of Grapefruit Juice on the Pharmacokinetics of Tadalafil in Rats. <i>BioMed research international</i> 2020 1631735–None. DOI:<a href=&quot;https://doi.org/10.1155/2020/1631735&quot;>10.1155/2020/1631735</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32047806/&quot;>https://pubmed.ncbi.nlm.nih.gov/32047806</a></p></li><li><p>Forgue, ST, et al., &amp; Mitchell, MI (2006). Tadalafil pharmacokinetics in healthy subjects. <i>British journal of clinical pharmacology</i> 61(3) 280–288. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.2005.02553.x&quot;>10.1111/j.1365-2125.2005.02553.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16487221/&quot;>https://pubmed.ncbi.nlm.nih.gov/16487221</a></p></li><li><p>Porat, D, et al., &amp; Dahan, A (2024). Erectile Dysfunction Therapy of Bariatric Patients: Tadalafil Biopharmaceutics and Pharmacokinetics Before vs. After Gastric Sleeve/Bypass. <i>The AAPS journal</i> 26(6) 114–None. DOI:<a href=&quot;https://doi.org/10.1208/s12248-024-00985-9&quot;>10.1208/s12248-024-00985-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39543061/&quot;>https://pubmed.ncbi.nlm.nih.gov/39543061</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G04BE08;
